APHA
Back to Annual Meeting Page
 
American Public Health Association
133rd Annual Meeting & Exposition
December 10-14, 2005
Philadelphia, PA
APHA 2005
 
3224.0: Monday, December 12, 2005 - 1:05 PM

Abstract #116539

Current policy opportunities to rein in the power of Big Pharma: What can the women’s health movement contribute?

Cynthia A. Pearson, National Women's Health Network, 514 Tenth Street, NW, Fourth Floor, Washington, DC 20004, 202-347-1140, cpearson@womenshealthnetwork.org

The United States is the global profit center for the pharmaceutical industry. The ability to make relatively unrestricted profits here is zealously defended by Big Pharma, leading to public policy that creates barriers to the expansion of basic and comprehensive health care for all. Reining in the power of Big Pharma is one of several necessary steps towards universal health care in the United States. But how? And by whom? The women's health movement has a substantial history of making change in health care in the United States. Over the last forty years, women's health activists have changed who can become a doctor, what doctors can do, how patients are treated and what they have a right to know. The movement's skills in identifying important issues and catalyzing grassroots action, if applied to Big Pharma, have the potential to build support for greater societal oversight and control of the pharmaceutical industry, similar to society's greater oversight of the medical profession. What are the opportunities for oversight, control and ultimately reining in the power of Big Pharma? This presentation will cover current policy opportunities and the role that the women's health movement can play in advocating for change.

Learning Objectives: At the conclusion of this presentation, participants will be able to

Keywords: Universal Health Care, Women's Health

Related Web page: www.nwhn.org

Presenting author's disclosure statement:

I wish to disclose that I have NO financial interests or other relationship with the manufactures of commercial products, suppliers of commercial services or commercial supporters.

Critical Perspectives on Pharmaceutical Corporations

The 133rd Annual Meeting & Exposition (December 10-14, 2005) of APHA